METTL3 as a potential therapeutic target in gastric cancer DOI Creative Commons
Zhigang Yu, Yang Yang

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 29, 2024

Gastric cancer (GC) is one of the leading causes cancer-related death worldwide. N6-methyladenosine (m6A) modification most prominent epigenetic eukaryotic mRNAs, and methyltransferase-like 3 (METTL3), a core component methyltransferase complex, catalyzes m6A modification. The results previous studies indicate that expression level METTL3 significantly elevated in gastric tissues cells. In addition, fluctuations levels induced by are closely associated with malignant progression tumors as well poor prognosis patients cancer. this review, we focus on potential mechanism cancer, through our analysis, suggest targeting could be new therapeutic tool for treating GC.

Language: Английский

Patent landscape of small molecule inhibitors of METTL3 (2020-present) DOI
Zhixing Wu, Alexis R. Smith, Zhijian Qian

et al.

Expert Opinion on Therapeutic Patents, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 16

Published: Dec. 25, 2024

Introduction Methyltransferase-like protein 3 (METTL3), in complex with METTL14, is the key 'writer' for RNA m6A methylation, accounting almost all mRNA modifications. Recent studies reveal that METTL3 implicated development and progression of various types cancers. Targeting small molecule inhibitors represents a promising therapeutic strategy cancer.

Language: Английский

Citations

4
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors DOI

G. Li,

Wei Chen, Dan Liu

et al.

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 117560 - 117560

Published: March 1, 2025

Language: Английский

Citations

0
METTL3 as a potential therapeutic target in gastric cancer DOI Creative Commons
Zhigang Yu, Yang Yang

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 29, 2024

Gastric cancer (GC) is one of the leading causes cancer-related death worldwide. N6-methyladenosine (m6A) modification most prominent epigenetic eukaryotic mRNAs, and methyltransferase-like 3 (METTL3), a core component methyltransferase complex, catalyzes m6A modification. The results previous studies indicate that expression level METTL3 significantly elevated in gastric tissues cells. In addition, fluctuations levels induced by are closely associated with malignant progression tumors as well poor prognosis patients cancer. this review, we focus on potential mechanism cancer, through our analysis, suggest targeting could be new therapeutic tool for treating GC.

Language: Английский

Citations

0